These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38413275)

  • 21. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended interval dosing with ocrelizumab in multiple sclerosis.
    Novak F; Bajwa HM; Østergaard K; Berg JM; Madsen JS; Olsen DA; Urbonaviciute I; Illes Z; Stilund ML; Romme Christensen J; Bramow S; Sellebjerg F; Sejbaek T
    Mult Scler; 2024 Jun; 30(7):847-856. PubMed ID: 38646949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    Toorop AA; Wessels MHJ; Gelissen LMY; Hoitsma E; Zeinstra EMPE; van Rooij LC; van Munster CEP; Vennegoor A; Mostert JP; Wokke BHA; Kalkers NF; Hoogervorst ELJ; van Eijk JJJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige LGF; Kloosterziel ME; Arnoldus EPJ; van Dijk GW; Bouvy WH; Strijbis EMM; van Oosten BW; de Jong BA; Lissenberg-Witte BI; Rispens T; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    J Neurol Sci; 2024 Jul; 462():123102. PubMed ID: 38925067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
    Foley J; Xiong K; Hoyt T; Singh CM; Riddle E; de Moor C; Plavina T; Campbell N
    Mult Scler; 2023 Feb; 29(2):196-205. PubMed ID: 36377744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
    Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
    Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
    Pelle J; Briant AR; Branger P; Derache N; Arnaud C; Lebrun-Frenay C; Cohen M; Mondot L; De Seze J; Bigaut K; Collongues N; Kremer L; Ricard D; Bompaire F; Ohlmann C; Sallansonnet-Froment M; Ciron J; Biotti D; Pignolet B; Parienti JJ; Defer G
    Neurol Ther; 2023 Apr; 12(2):529-542. PubMed ID: 36763307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
    Chang I; Muralidharan KK; Campbell N; Ho PR
    J Clin Pharmacol; 2021 Mar; 61(3):339-348. PubMed ID: 32949472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab extended-interval dosing in a real-life setting.
    Jeantin L; Boudot de la Motte M; Deschamps R; Gueguen A; Gout O; Lecler A; Papeix C; Bensa C
    J Neurol Sci; 2023 Jul; 450():120689. PubMed ID: 37210938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended interval dosing of natalizumab: a two-center, 7-year experience.
    Bomprezzi R; Pawate S
    Ther Adv Neurol Disord; 2014 Sep; 7(5):227-31. PubMed ID: 25342976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
    Rolfes L; Pawlitzki M; Pfeuffer S; Nelke C; Lux A; Pul R; Kleinschnitz C; Kleinschnitz K; Rogall R; Pape K; Bittner S; Zipp F; Warnke C; Goereci Y; Schroeter M; Ingwersen J; Aktas O; Klotz L; Ruck T; Wiendl H; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34261812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Meng D; Sacco R; Disanto G; Widmer F; Jacober SLS; Gobbi C; Zecca C
    Mult Scler; 2024 Jun; 30(7):857-867. PubMed ID: 38767224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    Raffel J; Gafson AR; Dahdaleh S; Malik O; Jones B; Nicholas R
    PLoS One; 2017; 12(1):e0169546. PubMed ID: 28081190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
    Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
    Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.
    Zanghì A; Ferraro D; Callari G; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Moretti MC; Avolio C; D'Amico E
    Curr Neuropharmacol; 2024; 22(2):339-345. PubMed ID: 37876043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.